

organized by:



under the auspices of:



# MELANOMA BRIDGE 2015

Naples, Hotel Excelsior  
December 1<sup>st</sup> - 4<sup>th</sup>, 2015



## ORGANIZED BY



Fondazione Melanoma Onlus

## UNDER THE AUSPICES OF



Associazione Italiana di  
Oncologia Medica



European Society  
for Medical Oncology



National Cancer Institute  
"Fondazione G.Pascale"



Sidra Medical and Research  
Center



Society for Immunotherapy of  
Cancer

# GENERAL INFORMATION



## CME PROVIDER AND ORGANISING AGENCY:

3P Solution Srl  
Via Marradi 3, 20123 Milan  
Phone +39 02 36631574 | Fax +39 02 36631640  
Cell. +39 3496485434  
[www.3psolution.it](http://www.3psolution.it)  
[info@3psolution.it](mailto:info@3psolution.it)  
[info@melanomabridge.org](mailto:info@melanomabridge.org)

## OFFICIAL LANGUAGE:

The official language is English

## REGISTRATION:

Only registered attendees will be admitted to the meeting.

The registration fee includes:

- participation in the scientific program
- CME credits
- coffee breaks and lunches from December 2<sup>nd</sup> to 4<sup>th</sup>
- congress bag

Participants are kindly requested to inform us about any dietary habit (i.e. food allergies/intolerances, vegetarian or vegan habits).

Please register at 3P Solution desk (cash or credit card accepted).

## CONGRESS VENUE:

Hotel Excelsior  
Via Partenope, 48  
80121 - Naples  
Phone +39 081 7640111  
[www.eurostarshotels.com](http://www.eurostarshotels.com)



**E.C.M.**

Commissione Nazionale Formazione Continua



## CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Provider (code 327) and has a quality-management system that meets the requirements of UNI EN ISO 9001:2008, with CSQA certificate no. 23887.

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Melanoma Bridge 2015 has been accredited with 4.4 CME credits for 200 participants of the following professions: Medical Doctors, Pharmacists, Biologists, and Nurses.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

In order to receive credits, participants must:

1. Attend at least 80% of the accredited sessions
2. Complete the evaluation form at the end of the Congress
3. Complete and sign the participation statement at the end of the Congress

CME certificate attendance will be sent to the participants at the end of the evaluation procedure.

## MY ECM

Age.na.s has activated the service MyEcm (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer
2. Refer to the summary of events attended and credits earned
3. Provide an assessment of courses organized by the Provider

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

## ESMO-MORA ACCREDITATION:

Melanoma Bridge 2015 is accredited by ESMO for 16, category 1 ESMO-MORA points



## SCIENTIFIC PROGRAM

# SCIENTIFIC PROGRAM

December 1<sup>st</sup>, 2015

## OPENING CEREMONY \*\*

*Chairpersons:* **Paolo A. Ascierto**  
**Francesco M. Marincola**  
**Nicola Mozzillo**

**05.00 pm** Welcome and introduction  
**Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo**

**05.30 pm** Award lecture of Fondazione Melanoma:  
The quest toward the identification of the genetic determinants of  
cancer immune responsiveness  
**Francesco M. Marincola**

## PATIENTS MEET THE EXPERTS \*\*

*Chairpersons:* **Francesco de Lorenzo**  
**Giuseppe Palmieri**

**06.00 pm** Roundtable  
What's new for melanoma patients and experts in 2015  
**Francesco de Lorenzo** (European Cancer Patient Coalition)  
**Sara Vigna** (AIMaMe - Associazione Italiana Malati di Melanoma)  
**Valerie Guild** (AIM at Melanoma)  
**Chiara Puri Purini** (Melanomaltalia)  
**Sabrina Nardi** (Cittadinanzattiva)  
**Antonio Brancaccio** (Fondazione Melanoma Onlus)  
**Elisabetta Colangelo** (Fondazione Melanoma Onlus)

**07.30 pm** Welcome cocktail



# SCIENTIFIC PROGRAM

December 1<sup>st</sup>, 2015

## PATIENT ASSOCIATIONS MEETING\*\*

Organized by AIMaMe - Associazione Italiana Malati di Melanoma

*Moderatori:* **Francesco de Lorenzo**  
**Sara Vigna**

**08.00 pm** AIMaMe incontra i clinici  
**Paolo A. Ascierto, Nicola Mozzillo, Giuseppe Palmieri**

AIMaMe incontra le associazioni e le fondazioni impegnate nella lotta al melanoma:

**Valerie Guild** (AIM at Melanoma)

**Chiara Puri Purini** (Melanomaitalia)

**Antonio Brancaccio** (Fondazione Melanoma Onlus)

**Elisabetta Colangelo** (Fondazione Melanoma Onlus)



\*\*Not included in the CME accredited program

# SCIENTIFIC PROGRAM

December 2<sup>nd</sup>, 2015

## MOLECULAR AND IMMUNO ADVANCES

Chairpersons: **Gerardo Botti**  
**Ena Wang**

**09.00 am** Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma  
**Michael Davies**

**09.25 am** Insights from Sequencing the Melanoma Exome  
**Michael Krauthammer**

**09.50 am** Genomic, epigenomic and immune evolution of melanoma acquiring resistance to MAPK-targeted therapies  
**Roger Lo**

**10.15 am** Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance  
**Gennaro Ciliberto**

**10.40 am** *Break*

**10.55 am** Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance  
**Stefani Spranger**

**11.20 am** Endogenous T Cell Therapy: The Next Generation of Personalized Adoptive Cellular Therapy  
**Cassian Yee**

**11.45 am** Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma  
**Soldano Ferrone**



# SCIENTIFIC PROGRAM

December 2<sup>nd</sup>, 2015

**12.10 pm** Discussion on the best abstracts submitted on Molecular and Immuno advances  
**Gerardo Botti, Ena Wang**

**12.10 pm** Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs  
**Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling** Vemurafenib in Patients With BRAFV600 Mutation–Positive

**12.25 pm** Evaluation of prognostic and therapeutic potential of COX 2 and PD-L1 in primary and metastatic melanoma  
**Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Adriana Esposito, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti**

**12.40 pm** Metastatic Melanoma: Final Overall Survival Results of the BRIM-3 Study  
**Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur**



# SCIENTIFIC PROGRAM

December 2<sup>nd</sup>, 2015

**12.55 pm** Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma  
**Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok**

**01.10 pm** Lunch

**12.00 pm** Assemblea Generale di AIMaMe:  
Relazione del Presidente sull'attività svolta e sul bilancio provvisorio  
**Sara Vigna**

Il contributo di FAVO  
**Francesco de Lorenzo**

Approvazione del bilancio preventivo e del programma delle attività 2016

Elezione del Consiglio Direttivo

Indicazione di esperti per la nomina del Comitato Scientifico

**14.30 pm** Chiusura dell'Assemblea



# SCIENTIFIC PROGRAM

December 2<sup>nd</sup>, 2015

## COMBINATION THERAPIES

Chairpersons: **Paolo A. Ascierto**  
**Claus Garbe**

**02.10 pm** Harnessing radiotherapy to improve responses to immunotherapy  
in cancer  
**Sandra Demaria**

**02.35 pm** New Strategies in Combination Immune Therapy  
**Samir Khleif**

**03.00 pm** Targeting tumor tissue to increase innate sensing for immunotherapy  
**Yang Xin Fu**

**03.25 pm** Biomarkers for treatment decision?  
**Reinhard Dummer**

**03.50 pm** *Break*

**04.05 pm** Combining oncolytic therapies in the era of checkpoint inhibitors  
**Igor Puzanov**

**04.30 pm** Immune checkpoint blockade for melanoma: Should we combine  
or sequence ipilimumab and PD-1 antibody therapy?  
**Michael Postow**

**04.55 pm** Surgery as a therapeutic option in metastatic stage IV melanoma  
**Nicola Mozzillo**

**05.20 pm** Discussion on the best abstracts submitted on Combination  
Therapies  
**Paolo A. Ascierto, Claus Garbe**

# SCIENTIFIC PROGRAM

December 2<sup>nd</sup>, 2015

- 05.20 pm** Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts)  
**Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liskay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno**
- 05.35 pm** An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) (CheckMate 064)  
**F. Stephen Hodi, Geoff Gibney, Ryan Sullivan, Jeffrey A. Sosman, Craig L. Slingluff Jr, Donald P. Lawrence, Theodore F. Logan, Lynn M. Schuchter, Suresh Nair, Leslie Fecher, Elizabeth Buchbinder, Mary Ruisi, George Kong, Christine Horak, Jeffrey S. Weber**
- 05.50 pm** Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)  
**James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff,7 David Hogg, Andrew Hill, Matteo S. Carlino, Pascal Wolter, Celeste Lebbé, Jacob Schachter, Luc Thomas, Jessica C. Hassel, Paul Lorigan, Dana Walker, Joel Jiang, F. Stephen Hodi, Jedd D. Wolchok**

# SCIENTIFIC PROGRAM

December 2<sup>nd</sup>, 2012

**06.05 pm** Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma  
Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu

**06.20 pm** Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma  
Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar

**06.35 pm** Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma  
Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi

**06.50 pm** Conclusions  
Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo



# SCIENTIFIC PROGRAM

December 3<sup>rd</sup>, 2015

## NEWS ON IMMUNOTHERAPY

*Chairpersons:* **Michele Maio**  
**Giuseppe Palmieri**

**09.00 am** An update on adjuvant and neoadjuvant therapy for melanoma  
**Ahmad Tarhini**

**09.25 am** Overview of intralesional oncolytic therapy  
**Sanjiv Agarwala**

**09.50 am** Update on adjuvant ipilimumab EORTC18071, update on ongoing adjuvant pembrolizumab EORTC1325 trials  
**Alexander Eggermont**

**10.15 am** Sponsored Symposium\*\*  
PD-1 Immunotherapy: New Paradigms in the Treatment of Melanoma and Beyond

**10.15 am** Welcome and introduction  
**Paolo A. Ascierto**

**10.25 am** Immunotherapy: changing the treatment landscape of melanoma  
**Thomas F. Gajewski**

**10.50 am** Cancer Immunotherapy in the future: learnings from melanoma  
**Paolo A. Ascierto**

**11.10 am** Questions and answers  
**Paolo A. Ascierto, Thomas Gajewski**


sponsored by MSD

**11.15 am** Break

# SCIENTIFIC PROGRAM

December 3<sup>rd</sup>, 2015

- 11.30 am** Targeting multiple inhibitory pathways in melanoma  
**Hassane Zarour**
- 11.55 am** An Update on Oncolytic Virus Immunotherapy for the Treatment of Melanoma  
**Howard Kaufman**
- 12.20 pm** Improving Adoptive Immune Therapy using Genetically Engineered T cells  
**David Stroncek**
- 12.45 pm** Discussion on the best abstracts submitted on News in Immunotherapy  
**Michele Maio, Giuseppe Palmieri**
- 12.45 pm** Two-year survival and safety update in patients (pts) with treatment naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066  
**Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Carmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert**
- 01.00 pm** Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067  
**Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok**



# SCIENTIFIC PROGRAM

December 3<sup>rd</sup>, 2015

**01.15 pm** Efficacy and safety of nivolumab (NIVO) monotherapy in the treatment of advanced mucosal melanoma (MEL)  
**James Larkin, Sandra P. D'Angelo, Jeffrey A. Sosman, Celeste Lebbé, Benjamin Brady, Bart Neyns, Henrik Schmidt, Jessica C. Hassel, F. Stephen Hodi, Paul Lorigan, Kerry J. Savage, Wilson Miller, Peter Mohr, Ivan Marquez-Rodas, Julie Charles, Martin Kaatz, Mario Sznol, Jeffrey S. Weber, Alexander N. Shoushtari, Mary Ruisi, Joel Jiang, Jedd D. Wolchok**

**01.30 pm** *Lunch*





# SCIENTIFIC PROGRAM

December 3<sup>rd</sup>, 2015

## TUMOR MICROENVIRONMENT AND BIOMARKERS

*Chairpersons:* **Giuseppe Masucci**  
**Alessandro Testori**

- 02.30 pm** Biomarker development for Immuno-Oncology and Cancer  
ImmunoTherapy: Simultaneous Digital Counting of Nucleic-Acids  
and Proteins at 800-plex  
**Alessandra Cesano**
- 02.55 pm** Tumor and host factors mediating resistance to immunotherapy  
**Thomas F. Gajewski**
- 03.20 pm** Multiparameter pathologic assessment of the PD-1/PD-L1 pathway  
in melanoma  
**Janis M. Taube**
- 03.45 pm** Understanding immune and molecular determinants of response to  
melanoma therapy  
**Jennifer A. Wargo**
- 04.10 pm** *Break*
- 04.25 pm** Developing Cancer Immunotherapy Strategies that Change the  
Tumor Microenvironment and Eliminate Cancer  
**Bernard A. Fox**
- 04.50 pm** Myeloid cells and tumor exosomes: a crosstalk for assessing  
immunosuppression?  
**Licia Rivoltini**
- 05.15 pm** Update on the SITC Biomarker Taskforce: progress and challenges  
**Magdalena Thurin**

# SCIENTIFIC PROGRAM

December 3<sup>rd</sup>, 2015

**05.40 pm** Predictors of response to immune checkpoint blockade in metastatic melanoma

**Laurence Zitvogel**

**06.05 pm** Discussion on the best abstracts submitted on Tumor Microenvironment and Biomarkers

**Giuseppe Masucci, Alessandro Testori**

**06.05 pm** New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma

**Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi**

**06.20 pm** Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab

**Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont and Laurence Zitvogel**

**06.35 pm** Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients

**Anna Passarelli, Marco Tucci, Stefania Stucci, Francesco Mannavola, Mariaelena Capone, Gabriele Madonna, Paolo Antonio Ascierto, Franco Silvestris**

# SCIENTIFIC PROGRAM

December 3<sup>rd</sup>, 2015

**06.50 pm** Immunological prognostic factors in stage III melanomas  
**María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont and Laurence Zitvogel**

**07.05 pm** Conclusions  
**Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo**



# SCIENTIFIC PROGRAM

December 4<sup>th</sup>, 2015

## WORLD-WIDE IMMUNOSCORE TASK FORCE: AN UPDATE

*Chairpersons:* **Paolo A. Ascierto**  
**Francesco M. Marincola**  
**Jerome Galon**

**09.30 am** Immunoscore in the era of cancer immunotherapy  
**Jerome Galon**

**09.50 am** Immunoscore and immunoprofiling in melanoma  
**Paolo A. Ascierto**

**10.10 am** The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology  
**Tilman Rau**

**10.30 am** *Break*

**10.45 am** Next generation immunoprofiling  
**Carlo Bifulco**


**11.05 am** In search of personalized cancer immunotherapy  
**Giuseppe Masucci**

**11.25 am** The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer's patients  
**Franck Pages**

**11.45 am** Roundtable "World-Wide Immunoscore Task Force"  
**Paolo A. Ascierto, Francesco M. Marincola, Jerome Galon**

**12.30 pm** Conclusions  
**Paolo A. Ascierto, Francesco M. Marincola, Jerome Galon**

**12.45 pm** *Lunch*



# SCIENTIFIC PROGRAM

December 4<sup>th</sup>, 2015

ECONOMIC SUSTAINABILITY OF MELANOMA TREATMENTS:  
REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND MARKET  
ACCESS ISSUES

*Chairpersons:* **Paolo A. Ascierto**  
**Pier Luigi Canonico**

**02.00 pm** Nivolumab, the regulatory experience in immunotherapy  
**Jorge Camarero**

**02.20 pm** The point of view of the Italian Medicines Agency (AIFA)  
**Paolo Foggi \***

**02.40 pm** The point of view of the National Institute for Health and Care  
Excellence (NICE)  
**Deborah Morrison**

**03.00 pm** Break

**03.20 pm** Financial toxicity: an emerging problem  
**Francesco Perrone**

**03.40 pm** Evidence to optimize access for immunotherapies  
**Claudio Jommi**

**04.00 pm** The point of view of the patient associations  
**Francesco de Lorenzo, Valerie Guild**

**04.40 pm** Roundtable on the economic sustainability of melanoma  
treatments  
**Paolo A. Ascierto, Pier Luigi Canonico**



**Jorge Camarero, Francesco de Lorenzo, Paolo Foggi, Valerie  
Guild, Claudio Jommi, Deborah Morrison, Francesco Perrone,  
Paola Queirolo**

# SCIENTIFIC PROGRAM

December 4<sup>th</sup>, 2015

**05.25 pm** Conclusions


**Paolo A. Ascierto, Pier Luigi Canonico**



# POSTER SESSION

## MOLECULAR AND IMMUNO-ADVANCES

- P01** Human Melanoma Cells Resistant to B-RAF and MEK inhibition Exhibit Mesenchymal-like Features  
Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto and Emilia Caputo
- P02** Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors  
Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto
- P03** Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression  
Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino and Angela Iano
- P04** Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma  
Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld, Miklos Kasler



## POSTER SESSION

- P05** Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma  
**Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto**
- P06** HuR positively regulates migration of HTB63 melanoma cells  
**Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad**
- P07** Prolyl 4-(C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy  
**Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook**
- P08** Urokinase receptor antagonists: novel agents for the treatment of melanoma  
**Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero**
- P09** Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells  
**Francesco Mannavola, Stella D'Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris**
- P10** New insights in mitochondrial metabolic reprogramming in melanoma  
**Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida**



## POSTER SESSION

- P11** Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle  
**Stella D'Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris**

### COMBINATION THERAPIES


- P12** Chemoimmunotherapy elicits polyfunctional anti-tumor CD8+ T cells depending on the activation of an AKT pathway sustained by ICOS  
**Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile Angela Gismondi, Angela Santoni, Paola Nisticò**

- P13** Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients  
**Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglinò**

- P14** Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study  
**Gianluca Di Monta, Corrado Caracò, Massimiliano Di Marzo, Ugo Marone, Maria Luisa Di Cecilia, Nicola Mozzillo**

### NEWS IN IMMUNOTHERAPY

- P15** Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection  
**Francesco Sabbatino, Celeste Fucciello, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe**



## POSTER SESSION

- P16** Immunotherapy and hypophysitis: a case report  
Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo,  
Michele De Tursi

### TUMOR MICROENVIRONMENT AND BIOMARKERS

- P17** New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential  
Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti
- P18** Utility of simultaneous measurement of three serum tumor markers in melanoma patients  
Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca
- P19** The significance of various cut-off levels of Melanoma Inhibitory Activity in evaluation of cutaneous melanoma patients  
Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca
- P20** The long noncoding RNA hotair is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease  
Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino,  
**P21** Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto,  
Gerardo Botti, Monica Cantile



## POSTER SESSION

### OTHER

**P21** The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection

**Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi**

**P22** Epidemiological survey on related psychopathology in melanoma  
**Valeria De Biasio , Vincenzo C. Battarra**







**MELANOMA**  
**BRIDGE** 2015

PRESIDENCY  
SCIENTIFIC BOARD  
FACULTY

## PRESIDENCY



**Paolo A. Ascierto**

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy



**Francesco M. Marincola**

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar



**Nicola Mozzillo**

Director of the Department of Surgical Oncology B, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

## SCIENTIFIC BOARD

**Paolo A. Ascierto**

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

**Gennaro Ciliberto**

Scientific Director of the National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

**Reinhard Dummer**

University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

**Bernard A. Fox**

Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

## SCIENTIFIC BOARD

### **Claus Garbe**

University Professor of Dermatology, Head, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

### **John M. Kirkwood**

Professor of Medicine, Dermatology and Translational Science, Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute, Pennsylvania

### **Francesco M. Marincola**

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

### **Giuseppe Masucci**

Professor, Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

### **Ignacio Melero**

Professor of Immunology and Consultant, CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

### **Nicola Mozzillo**

Director of the Department of Surgical Oncology B, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

### **Giuseppe Palmieri**

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

### **Igor Puzanov**

Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee

### **Alessandro Testori**

Director of the Dermato-oncology Surgery Division, European Institute of Oncology, Milan, Italy

### **Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

## FACULTY

### **Sanjiv Agarwala**

St. Luke's University Hospital and Temple University, Bethlehem, Pennsylvania

### **Paolo A. Ascierto**

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

### **Carlo Bifulco**

Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

### **Gerardo Botti**

National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

### **Jorge Camarero**

Oncology Area, Spanish Agency for Medicines and Medical Devices, AEMPS, Spain , Oncology assessor at the European Medicines Agency, EMA

### **Alessandra Cesano**

NanoString Technologies, Seattle, Washington

### **Pier Luigi Canonico**

Department of Scienze del Farmaco, University of Piemonte Orientale, Novara, Italy

### **Gennaro Ciliberto**

National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

### **Michael Davies**

Department of Melanoma Medical Oncology, Department of Systems Biology, University of Texas MD Anderson Cancer Center, Texas

### **Francesco De Lorenzo**

Italian Federation of Volunteer-based Cancer Organizations, FAVO

### **Sandra Demaria**

New York University School of Medicine and NYU Langone Medical Center Alexandria Center for Life Sciences, New York



## FACULTY

**Reinhard Dummer**

University of Zurich Hospital, Department of Dermatology, Zurich

**Alexander Eggermont**

Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France

**Soldano Ferrone**

Massachusetts General Hospital, Boston, Massachusetts

**Paolo Foggi\***

Italian Medicines Agency, AIFA

**Bernard A. Fox**

Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

**Yang Xin Fu**

Donnelley Biological Sciences Learning Center, University of Chicago, Illinois

**Thomas F. Gajewski**

Department of Pathology and Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois

**Jerome Galon**

INSERM (National Institute of Health and Medical Research), Paris, France

**Claus Garbe**

Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany

**Valerie Guild**

AIM at Melanoma, Richmond, California

**Claudio Jommi**

Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy

**Howard Kaufman**

Rutgers Cancer Institute of New Jersey, New Jersey

## FACULTY

### **Samir Khleif**

Georgia Regents University Cancer Center, Augusta, Georgia

### **Michael Krauthammer**

Yale University School of Medicine, Department of Pathology, New Haven, Connecticut

### **Roger Lo**

Melanoma Clinic in Dermatology Member, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, California

### **Michele Maio**

Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Italy

### **Francesco M. Marincola**

Sidra Medical and Research Center, Doha, Qatar

### **Giuseppe Masucci**

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

### **Deborah Morrison**

National Institute for Health and Care Excellence, NICE

### **Nicola Mozzillo**

Department Melanoma and Soft Tissues, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

### **Franck Pages**

Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, Paris, France

### **Giuseppe Palmieri**

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

### **Francesco Perrone**

Clinical Trials Unit, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

## FACULTY

**Michael Postow**

Memorial Sloan Kettering Cancer Center, New York

**Igor Puzanov**

Division of Hematology-Oncology, Vanderbilt University Medical Center,  
Nashville, Tennessee

**Tilman Rau**

Institute of Pathology, University of Bern, Switzerland

**Licia Rivoltini**

National Cancer Institute of Milan, Italy

**Paola Queirolo**

National Institute for Cancer Research, Genova, Italy

**Stefani Spranger**

Department of Patholog, University of Chicago, Illinois

**David Frank Stroncek**

Department of Transfusion Medicine, NIH Clinical Center, Bethesda,  
Maryland

**Ahmad Tarhini**

Melanoma and Skin Cancer Program University of Pittsburgh Cancer  
Institute, Pennsylvania

**Janis M. Taube**

Johns Hopkins University SOM, Baltimore, Maryland

**Alessandro Testori**

Dermato-oncology Surgery Division, European Institute of Oncology,  
Milan, Italy

**Magdalena Thurin**

Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis,  
NCI, NIH, Rockville, Maryland

**Ena Wang**

Sidra Medical and Research Centre, Doha, Qatar

## FACULTY

### **Jennifer A. Wargo**

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

### **Cassian Yee**

Solid Tumor Cell Therapy and ACT Platform, UT MD Anderson Cancer Center, Texas

### **Hassane Zarour**

University of Pittsburgh Cancer Institute Hillman Cancer Center, Pennsylvania

### **Laurence Zitvogel**

Institut Gustave Roussy, Villejuif, Paris-Sud, France



*\* To be confirmed*



Melanoma Bridge 2015 is sponsored by an unrestricted grant from:

---

**PLATINUM SPONSOR**



**MSD** ONCOLOGY

**SILVER SPONSOR**



**BRONZE SPONSOR**



**SPONSOR**

